c-Fos oncogene regulator Elk-1 interacts with BRCA1 splice variants BRCA1a/1b and enhances BRCA1a/1b-mediated growth suppression in breast cancer cells

被引:48
|
作者
Chai, YL [1 ]
Chipitsyna, G [1 ]
Cui, JQ [1 ]
Liao, BS [1 ]
Liu, S [1 ]
Aysola, K [1 ]
Yezdani, M [1 ]
Reddy, ESP [1 ]
Rao, VN [1 ]
机构
[1] Med Coll Penn & Hahnemann Univ, Ctr Canc, Dept Med, Program Canc Genet, Philadelphia, PA 19102 USA
关键词
c-Fos; BRCA1/BRCA1a/1b; Elk-1; growth suppression; breast cancer; protein-protein interaction;
D O I
10.1038/sj.onc.1204256
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Elk-1, a c-Fos protooncogene regulator, which belongs to the ETS-domain family of transcriptional factors, plays an important role in the induction of immediate early gene expression in response to a variety of extracellular signals. In this study, we demonstrate for the first time the in, vitro and in vivo interaction of Elk-1 with BRCA1 splice variants BRCA1a and BRCA1b using GST-pull down assays, co-imunoprecipitations/Western blot analysis of cell extracts from breast cancer cells and mammalian two-hybrid assays. We have localized the BRCA1 interaction domain of Elk-1 protein to the conserved ETS domain, a motif involved in DNA binding and protein-protein interactions. We also observed binding of BRCA1 proteins to other ETS-domain transcription factors SAP1, ETS-1, ERG-2 and Fli-1 but not to Elk-1 splice variant Delta Elk-1 and c-Fos protooncogene, Both BRCA1a and BRCA1b splice variants function as growth suppressors of human breast cancer cells. interestingly, our studies reveal that although both Elk-1 and SAP-1 are highly homologous members of a subfamily of ETS domain proteins called ternary complex factors, it is only Elk-1 but not SAP-I that can augment the growth suppressive function of BRCA1a/1b proteins in breast cancer cells, Thus Elk-1 could be a potential downstream target of BRCA1 in its growth control pathway, Furthermore, we hare observed inhibition of c-Fos promoter activity in BRCA1a transfected stable breast cancer cells and over expression of BRCA1a/1b attenuates MEK-induced SRE activation in vivo. These results demonstrate for the first time a link between the growth suppressive function of BRCA1a/1b proteins and signal transduction pathway involving Elk-1 protein, All these results taken together suggest that one of the mechanisms by which BRCA1a/1b proteins function as growth/tumor suppressors is through inhibition of the expression of Elk-1 target genes like c-Fos.
引用
收藏
页码:1357 / 1367
页数:11
相关论文
共 50 条
  • [21] Haplotype analysis of BRCA1/BRCA2 variants in Korean patients with breast cancer
    Kwon, Won Kyung
    Jang, Hyeok-Jae
    Jang, Ja-Hyun
    Lee, Jeong Eon
    Park, Yeon Hee
    Kim, Jong-Won
    GENETIC EPIDEMIOLOGY, 2020, 44 (05) : 489 - 490
  • [22] Exploring genetic variants of BRCA1 and BRCA2 in Indian Breast Cancer cases
    Ray, Manisha
    Banik, Suranjana
    Dash, Shilpi Samikshya
    Sable, Mukund Namdev
    HUMAN GENE, 2022, 34
  • [23] BRCA1 and BRCA2 sequence variants in Algerian breast/ovarian cancer families
    Cherbal, Farid
    Benais-Pont, Gaelle
    Bakour, Rabah
    Adane, Saida
    Boualga, Kada
    Maillet, Philippe
    CANCER RESEARCH, 2010, 70
  • [24] Risk of contralateral breast cancer associated with common variants in BRCA1 and BRCA2: potential modifying effect of BRCA1/BRCA2 mutation carrier status
    Jane C. Figueiredo
    Jennifer D. Brooks
    David V. Conti
    Jenny N. Poynter
    Sharon N. Teraoka
    Kathleen E. Malone
    Leslie Bernstein
    Won D. Lee
    David J. Duggan
    Ashley Siniard
    Patrick Concannon
    Marinela Capanu
    Charles F. Lynch
    Jørgen H. Olsen
    Robert W. Haile
    Jonine L. Bernstein
    Breast Cancer Research and Treatment, 2011, 127 : 819 - 829
  • [25] Risk of contralateral breast cancer associated with common variants in BRCA1 and BRCA2: potential modifying effect of BRCA1/BRCA2 mutation carrier status
    Figueiredo, Jane C.
    Brooks, Jennifer D.
    Conti, David V.
    Poynter, Jenny N.
    Teraoka, Sharon N.
    Malone, Kathleen E.
    Bernstein, Leslie
    Lee, Won D.
    Duggan, David J.
    Siniard, Ashley
    Concannon, Patrick
    Capanu, Marinela
    Lynch, Charles F.
    Olsen, Jorgen H.
    Haile, Robert W.
    Bernstein, Jonine L.
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 127 (03) : 819 - 829
  • [26] BRCA1 suppresses osteopontin-mediated breast cancer
    El-Tanani, Mohamed K.
    Campbell, Frederick Charles
    Crowe, Paul
    Erwin, Pauline
    Harkin, Denis Paul
    Pharoah, Paul
    Ponder, Bruce
    Rudland, Philip S.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (36) : 26587 - 26601
  • [27] BRCA1 promoter methylation of normal breast epithelial cells as a possible precursor for BRCA1-methylated breast cancer
    Otani, Yoko
    Miyake, Tomohiro
    Kagara, Naofumi
    Shimoda, Masafumi
    Naoi, Yasuto
    Maruyama, Naomi
    Shimomura, Atsuhi
    Shimazu, Kenzo
    Kim, Seung Jin
    Noguchi, Shinzaburo
    CANCER SCIENCE, 2014, 105 (10) : 1369 - 1376
  • [28] Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-Delta 11b
    Wilson, CA
    Payton, MN
    Elliott, GS
    Buaas, FW
    Cajulis, EE
    Grosshans, D
    Ramos, L
    Reese, DM
    Slamon, DJ
    Calzone, FJ
    ONCOGENE, 1997, 14 (01) : 1 - 16
  • [29] Differential response of BRCA1 wild type and BRCA1 mutant breast cancer cells to ionizing radiation and paclitaxel.
    Ren, Q
    Carbonne, C
    Potoczek, M
    Krajewska, M
    Krajewski, S
    Basu, A
    Haldar, S
    Reed, J
    Turner, B
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3723S - 3723S
  • [30] BRCA1 promoter methylation in peripheral blood cells is associated with increased risk of breast cancer with BRCA1 promoter methylation
    Iwamoto, Takashi
    Yamamoto, Noriaki
    Taguchi, Tetsuya
    Tamaki, Yasuhiro
    Noguchi, Shinzaburo
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 129 (01) : 69 - 77